Literature DB >> 18656460

Purification and mass spectrometric analysis of the kappa opioid receptor.

Kenneth M Wannemacher1, Alexandra Terskiy, Shengjie Bian, Prem N Yadav, Hong Li, Richard D Howells.   

Abstract

A clonal human embryonic kidney (HEK) 293 cell line was established that stably expressed the rat kappa-opioid receptor (rKOR) with a FLAG epitope at the amino terminus. The Kd for [3H]diprenorphine was 1.1+/-0.2 nM, and the Bmax was 2.6+/-0.4 pmol/mg. Dynorphin A (1-13), U69,593 and naloxone competitively inhibited [3H]diprenorphine binding with Ki values of 2.0, 18 and 18 nM, respectively, in good agreement with previously reported affinities for the unmodified receptor. U69,593 stimulated [35S]GTPgammaS binding in a concentration-dependent manner and caused phosphorylation of mitogen-activated protein (MAP) kinase, indicating that the activated epitope-tagged receptor triggered appropriate signaling pathways. Immunoblot analysis demonstrated that two immunoreactive receptor species with apparent molecular masses of 42 and 52 kDa were expressed. Previous studies indicated that the 42 kDa protein was localized intracellularly and was a precursor of the 52 kDa receptor, which was present at the cell surface. rKOR was extracted from transfected HEK 293 cell membranes with n-dodecyl-beta-D-maltopyranoside. Sequential use of wheat germ agglutinin chromatography, Sephacryl S300 gel filtration chromatography, anti-FLAG immunoaffinity chromatography and SDS/PAGE permitted purification of the 52 kDa receptor. MALDI-TOF mass spectrometry was used to identify peptides derived from rKOR following sequential in-gel digestion with trypsin and cyanogen bromide. Eighteen rKOR peptides were detected, corresponding to 27.1% coverage of the receptor. Precursor-selective MS/MS confirmed the identity of most of these peptides. In addition, we have identified heat shock protein 70 (HSP70) as a rKOR-interacting protein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18656460      PMCID: PMC2570952          DOI: 10.1016/j.brainres.2008.06.121

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  58 in total

Review 1.  Cellular and synaptic adaptations mediating opioid dependence.

Authors:  J T Williams; M J Christie; O Manzoni
Journal:  Physiol Rev       Date:  2001-01       Impact factor: 37.312

2.  High-throughput mass spectrometric discovery of protein post-translational modifications.

Authors:  M R Wilkins; E Gasteiger; A A Gooley; B R Herbert; M P Molloy; P A Binz; K Ou; J C Sanchez; A Bairoch; K L Williams; D F Hochstrasser
Journal:  J Mol Biol       Date:  1999-06-11       Impact factor: 5.469

3.  Cloning of a delta opioid receptor by functional expression.

Authors:  C J Evans; D E Keith; H Morrison; K Magendzo; R H Edwards
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

4.  Combined in-gel tryptic digestion and CNBr cleavage for the generation of peptide maps of an integral membrane protein with MALDI-TOF mass spectrometry.

Authors:  Bart A van Montfort; Mark K Doeven; Benito Canas; Liesbeth M Veenhoff; Bert Poolman; George T Robillard
Journal:  Biochim Biophys Acta       Date:  2002-09-10

5.  A member of the heat shock protein 40 family, hlj1, binds to the carboxyl tail of the human mu opioid receptor.

Authors:  N Ancevska-Taneva; I Onoprishvili; M L Andria; J M Hiller; E J Simon
Journal:  Brain Res       Date:  2006-03-20       Impact factor: 3.252

6.  Mass spectrometric analysis of agonist effects on posttranslational modifications of the beta-2 adrenoceptor in mammalian cells.

Authors:  Michelle Trester-Zedlitz; Al Burlingame; Brian Kobilka; Mark von Zastrow
Journal:  Biochemistry       Date:  2005-04-26       Impact factor: 3.162

7.  Lectin binding of solubilized opiate receptors: evidence for their glycoprotein nature.

Authors:  T Gioannini; B Foucaud; J M Hiller; M E Hatten; E J Simon
Journal:  Biochem Biophys Res Commun       Date:  1982-04-14       Impact factor: 3.575

8.  Purification and mass spectrometric analysis of the mu opioid receptor.

Authors:  Keith H Christoffers; Hong Li; Susan M Keenan; Richard D Howells
Journal:  Brain Res Mol Brain Res       Date:  2003-10-21

9.  Stereospecific binding of the potent narcotic analgesic (3H) Etorphine to rat-brain homogenate.

Authors:  E J Simon; J M Hiller; I Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-07       Impact factor: 11.205

Review 10.  Agonist-induced regulation and trafficking of kappa opioid receptors.

Authors:  Lee-Yuan Liu-Chen
Journal:  Life Sci       Date:  2004-06-18       Impact factor: 5.037

View more
  5 in total

1.  Proteomic profiling of renal allograft rejection in serum using magnetic bead-based sample fractionation and MALDI-TOF MS.

Authors:  Weiguo Sui; Liling Huang; Yong Dai; Jiejing Chen; Qiang Yan; He Huang
Journal:  Clin Exp Med       Date:  2010-04-08       Impact factor: 3.984

2.  Naltrindole inhibits human multiple myeloma cell proliferation in vitro and in a murine xenograft model in vivo.

Authors:  Jyoti Joshi Mundra; Alexandra Terskiy; Richard D Howells
Journal:  J Pharmacol Exp Ther       Date:  2012-04-26       Impact factor: 4.030

3.  Pharmacological and phosphoproteomic approaches to roles of protein kinase C in kappa opioid receptor-mediated effects in mice.

Authors:  Jeffrey J Liu; Yi-Ting Chiu; Chongguang Chen; Peng Huang; Matthias Mann; Lee-Yuan Liu-Chen
Journal:  Neuropharmacology       Date:  2020-09-22       Impact factor: 5.250

4.  Identification of phosphorylation sites in the COOH-terminal tail of the μ-opioid receptor.

Authors:  Ying-Ju Chen; Sue Oldfield; Adrian J Butcher; Andrew B Tobin; Kunal Saxena; Vsevolod V Gurevich; Jeffrey L Benovic; Graeme Henderson; Eamonn Kelly
Journal:  J Neurochem       Date:  2012-11-30       Impact factor: 5.372

5.  Proteomic profiling of nephrotic syndrome in serum using magnetic bead based sample fractionation & MALDI-TOF MS.

Authors:  Weiguo Sui; Yong Dai; Yue Zhang; Jiejing Chen; Huaying Liu; He Huang
Journal:  Indian J Med Res       Date:  2012-03       Impact factor: 2.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.